

	Biosimilar	Manufacturer and year of approval	Review time (from filing to the earlier of approval and IP hold, where available)	Medicinal ingredient	Marketed?
1	OMNITROPE	Sandoz, 2009	748 days	somatropin	yes
2, 3	REMSIMA/INFLECTRA	Celltrion, Hospira 2014	427 days	infliximab	yes (INFLECTRA)
4	BASAGLAR	Eli Lilly, 2015	356 days	insulin glargine	yes
5	GRASTOFIL	Apotex, 2015	1039 days¹	filgrastim	yes
6	BRENZYS	Samsung Bioepis, 2016	358 days	etanercept	yes
7	ERELZI	Sandoz, 2017	353 days	etanercept	yes
8	ADMELOG	Sanofi-aventis, 2017	351 days	insulin lispro	yes
9	RENFLEXIS	Samsung Bioepis, 2017	793 days	infliximab	yes
10	HADLIMA, HADLIMA PUSH TOUCH	Samsung Bioepis, 2018	432 days	adalimumab	no
11	LAPELGA	Apotex, 2018	349 days	pegfilgrastim	yes
12	MVASI	Amgen, 2018	358 days	bevacizumab	yes
13	FULPHILA	Mylan, 2018	754 days	pegfilgrastim	yes
14	TRUXIMA	Celltrion, 2019	335 days	rituximab	yes
15	OGIVRI	BGP Pharma, 2019	356 days	trastuzumab	yes
16	ZIRABEV	Pfizer, 2019	336 days	bevacizumab	yes
17	TRAZIMERA	Pfizer, 2019	348 days	trastuzumab	yes
18	HERZUMA	Celltrion, 2019	324 days	trastuzumab	yes
19	OSNUVO	Avir Pharma, January 2020	637 days	teriparatide	no
20	KANJINTI	Amgen, February 2020	920 days	trastuzumab	yes
21	AVSOLA	Amgen, March 2020	351 days	infliximab	yes
22	NIVESTYM	Pfizer, April 2020	345 days	filgrastim	yes
23	ZIEXTENZO	Sandoz, April 2020	336 days	pegfilgrastim	yes
24	RIXIMYO	Sandoz, April 2020	795 days	rituximab	yes
25	RUXIENCE	Pfizer, May 2020	344 days	rituximab	yes